March 31st 2025EP. 2: Introduction to IgA Nephropathy
Panelists discuss how immunoglobulin A (IgA) nephropathy represents a complex glomerular disease characterized by IgA deposition in the mesangium, with a wide spectrum of clinical presentations ranging from benign hematuria to progressive kidney failure requiring comprehensive management strategies.
April 14th 2025EP. 5: Signs and Symptoms of IgA Nephropathy
Panelists discuss how patients with immunoglobulin A (IgA) nephropathy typically present with microscopic or gross hematuria, often during upper respiratory infections, along with variable proteinuria and sometimes hypertension or decreased kidney function.
April 14th 2025EP. 6: Challenges in Timely Identification of IgA Nephropathy
Panelists discuss how diagnostic challenges in immunoglobulin A (IgA) nephropathy lead to delayed identification, missed treatment windows, and increased risk of irreversible kidney damage due to the requirement for invasive biopsy, nonspecific symptoms, and variable disease presentation.
April 21st 2025EP. 7: Clinical Impact of IgA Nephropathy and Quality of Life
Panelists discuss how immunoglobulin A (IgA) nephropathy significantly impacts patients’ quality of life through chronic symptoms, treatment burden, psychological effects, and the looming threat of progressive kidney function decline.
April 21st 2025EP. 9: Current Treatments for IgA Nephropathy and the 4-Hit Cascade
Panelists discuss how current immunoglobulin A (IgA) nephropathy treatments primarily target downstream inflammatory pathways of the 4-hit cascade, with emerging therapies now beginning to address specific upstream mechanisms including abnormal IgA1 production, autoantibody formation, and immune complex deposition.
April 21st 2025EP. 10: Gaps in Patient Care for IgA Nephropathy
Panelists discuss how significant gaps in immunoglobulin A (IgA) nephropathy patient care persist, including delayed diagnosis, limited access to nephrology expertise, inadequate disease monitoring, and insufficient psychosocial support throughout the disease journey.
April 28th 2025EP. 11: Emerging Anti-BATH- and Anti-APRIL Therapies
Panelists discuss how novel targeted therapies for immunoglobulin A (IgA) nephropathy are transforming treatment paradigms by specifically addressing the underlying pathophysiology of the 4-hit cascade rather than broadly suppressing inflammation.
April 28th 2025EP. 12: Emerging Therapies: Other Strategies and Important Considerations
Panelists discuss how targeted therapies for immunoglobulin A (IgA) nephropathy are advancing rapidly, with promising results from trials of B-cell modulating agents that inhibit APRIL/BAFF signaling and complement pathway inhibitors that address specific steps in the 4-hit cascade.